Esperion Therapeutics Stock News

Apellis Pharmaceuticals (NASDAQ:APLS) initiated with Strong Buy rating and $86 (221% upside) price target at Raymond James.BioXcel Therapeutics (NASDAQ:BTAI) initiated with Buy rating and $45 (101% up

Esperion initiated with a Buy at BofA BofA ESPR

In a report released today, Chad Messer from Needham reiterated a Buy rating on Esperion (ESPR), with a price target of $158.00. The company's shares

In a report released today, Chad Messer from Needham reiterated a Buy rating on Esperion (ESPR – Research Report), with

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 30.) Athersys Inc (NASDAQ:...

Axa purchased a new position in Esperion Therapeutics Inc (NASDAQ:ESPR) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commissi

Esperion (ESPR) announced today that NEXLETOL™ (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine is now available in U.S. pharmacies. Esperion is c

– First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine in the U.S. in Nearly 20 Years for Indicated Patients Awaiting a New Option ––...

Esperion announces commercial availability of Nexletol tablet in the U.S. ESPR

Esperion Therapeutics (NASDAQ:ESPR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday, Zacks.com reports. The

Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) today announced results from two pooled analyses from four Phase 3 clinical trials for bempedoic acid and separate results from a Phase 2 s

Esperion Therapeutics Inc (NASDAQ:ESPR)’s stock price traded down 5.6% during mid-day trading on Friday . The company traded as low as $35.24 and last traded at $35.29, 525,267 shares changed hands

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.